Rockland Trust Co. Invests $202,000 in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Rockland Trust Co. purchased a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 400 shares of the company’s stock, valued at approximately $202,000.

A number of other hedge funds have also added to or reduced their stakes in IDXX. Atomi Financial Group Inc. increased its position in shares of IDEXX Laboratories by 3.4% during the 1st quarter. Atomi Financial Group Inc. now owns 637 shares of the company’s stock valued at $344,000 after purchasing an additional 21 shares during the last quarter. Ballentine Partners LLC raised its position in IDEXX Laboratories by 1.9% in the first quarter. Ballentine Partners LLC now owns 1,188 shares of the company’s stock worth $641,000 after acquiring an additional 22 shares during the period. Eads & Heald Wealth Management boosted its stake in IDEXX Laboratories by 0.8% in the second quarter. Eads & Heald Wealth Management now owns 2,686 shares of the company’s stock valued at $1,309,000 after acquiring an additional 22 shares during the last quarter. LRI Investments LLC grew its position in shares of IDEXX Laboratories by 21.7% during the 2nd quarter. LRI Investments LLC now owns 129 shares of the company’s stock valued at $63,000 after acquiring an additional 23 shares during the period. Finally, Mather Group LLC. increased its stake in shares of IDEXX Laboratories by 4.2% during the 2nd quarter. Mather Group LLC. now owns 594 shares of the company’s stock worth $321,000 after purchasing an additional 24 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on IDXX shares. BTIG Research assumed coverage on IDEXX Laboratories in a report on Thursday, July 25th. They issued a “buy” rating and a $580.00 price objective for the company. Stifel Nicolaus reduced their target price on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a research note on Monday, June 24th. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. Finally, Piper Sandler lowered their target price on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a report on Wednesday, August 14th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and an average target price of $582.25.

IDEXX Laboratories Trading Down 1.2 %

Shares of NASDAQ:IDXX traded down $5.85 on Friday, hitting $477.67. The company had a trading volume of 468,682 shares, compared to its average volume of 468,802. The firm’s 50-day simple moving average is $487.95 and its two-hundred day simple moving average is $496.16. The firm has a market capitalization of $39.45 billion, a price-to-earnings ratio of 46.24, a P/E/G ratio of 4.32 and a beta of 1.33. The company has a quick ratio of 1.03, a current ratio of 1.37 and a debt-to-equity ratio of 0.33. IDEXX Laboratories, Inc. has a 1 year low of $372.50 and a 1 year high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $2.44 earnings per share for the quarter, missing the consensus estimate of $2.88 by ($0.44). IDEXX Laboratories had a net margin of 22.34% and a return on equity of 57.03%. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the previous year, the firm posted $2.67 earnings per share. The business’s revenue was up 6.4% compared to the same quarter last year. Equities analysts anticipate that IDEXX Laboratories, Inc. will post 10.45 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.